What Atea Pharmaceuticals, Inc. does.

We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care (“SOC”) for the treatment of patients with hepatitis C virus (“HCV”) infection and AT-587 which we believe has the potential to be the first direct-acting antiviral (“DAA”) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (“HEV”) infection.

The objective of our HCV development program is to improve upon the current SOC by offering bemnifosbuvir and ruzasvir as a differentiated pan-genotypic protease inhibitor-free, short-duration regimen for patients infected with HCV, if successfully developed and approved. We believe that a novel treatment regimen that can be easily prescribed will benefit today’s HCV population, which is predominately young (20-49 years old) and non-cirrhotic, and it would be a significant improvement to the current SOC.

Revenue and profit, by fiscal year.

More on AVIR.

• Atea Pharmaceuticals, Inc. summary
• Atea Pharmaceuticals, Inc. financial statements
• Atea Pharmaceuticals, Inc. key metrics
• Atea Pharmaceuticals, Inc. health scores and style box
• Atea Pharmaceuticals, Inc. earnings
• Atea Pharmaceuticals, Inc. dividends
• Atea Pharmaceuticals, Inc. valuation
• Atea Pharmaceuticals, Inc. ownership and insiders
• Atea Pharmaceuticals, Inc. peers

Figures from Atea Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.